Record mula sa primary source
Decision-gradePagbabago sa trial registry
RNXT: kumpleto na ang enrollment ng Phase 3 TIGeR-PaC; topline data sa H2 2027
Phase III TIGeR-PaC trial evaluating intra-arterial gemcitabine via RenovoCath reached full enrollment. Trial completion expected in H1 2027 after 86 events; topline data readout now guided for H2 2027. 15 trial sites are positioned to transition to commercial RenovoCath use.
Mahahalagang fact
- Na-file
- Ago 13, 2026, 08:06 PM
- Kaganapan
- Pagbabago sa trial registry
- Direksyon
- Neutral
- Kumpanya
RNXTRenovoRx, Inc.- Asset
- RenovoCath
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
- aktibong sentro
- 21
- Mga pangyayaring naobserbahan
- 78 sa 86
- kita q2 2026
- $909,000
- Mga sentro sa pipeline
- 63
- Gabay sa kita 2026
- $3.75M-$4.25M
Sipi mula sa source
EX-99.1 2 rnxt-ex99_1.htm EX-99.1 EX-99.1 RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth Increases 2026 Annual Revenue Guidance to a Range of $3.75M to $4.25M First Treatment Delivered with RenovoCath ® in Patient with Sarcoma in Clinical Setting, Marking Expansion of Device to Other Solid Tumors Phase III TIGeR-PaC Trial Reaches Full Enrollment; Completion of Trial Expected in First Half 2027 with Topline Data Readout Expected in Second Half 2027 Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif. – August 12, 2026 – RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies and commercializin
Higit pa tungkol sa asset na ito
Kapansin-pansin
Ago 4, 2026
08:10 PM
RNXTRenovoRx, Inc.Itatampok ng RenovoRx ang TAMP Platform sa JonesTrading KOL Webinar tungkol sa pancreatic cancer
Kapansin-pansin
Mar 30, 2026
09:38 PM
RNXTRenovoRx, Inc.RenovoRx: nasa tamang landas ang enrollment ng Phase 3 TIGeR-PaC para sa kalagitnaan ng 2026